Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06901531
What this trial is testing

Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc. 500
Large-scale testing (Phase 3)Not Yet RecruitingNCT07716449
What this trial is testing

QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
Qilu Pharmaceutical Co., Ltd. 560
Very early researchLooking for participantsNCT07595237
What this trial is testing

A IIT Study of 177Lu-DOTA-SNA040

Who this might be right for
Advanced Solid Tumors (Such as Gastric Cancer)Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction)Advanced Solid Tumors (Such as Pancreatic Cancer)+1 more
SmartNuclide Biopharma 12
Testing effectiveness (Phase 2)Looking for participantsNCT07483567
What this trial is testing

IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
CLDN18.2 PositivePrimary Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd. 90
Not applicableAvailableNCT06048081
What this trial is testing

Early Access Program for Zolbetuximab

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma CancerLocally Advanced Unresectable Gastric Adenocarcinoma CancerMetastatic Gastric Adenocarcinoma Cancer+1 more
Astellas Pharma Global Development, Inc.
Early research (Phase 1)UnknownNCT05472857
What this trial is testing

Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

Who this might be right for
Gastric CancerPancreatic CancerAdvanced Ovarian Carcinoma+1 more
Suzhou Immunofoco Biotechnology Co., Ltd 30
Large-scale testing (Phase 3)Looking for participantsNCT07584135
What this trial is testing

JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Adenocarcinoma
NingBo Junyan Hongshi Biosciences Co., Ltd 600